 | This article needs additional citations for verification. (September 2015) |
The Alliance for Clinical Trials in Oncology is a national clinical trials network sponsored by the National Cancer Institute (NCI) that consists of about 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada.[1] The Alliance develops and conducts clinical trials with promising new cancer therapies, and utilizes scientific research to develop treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments.[2]
The Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. The Alliance conducts trials in the following disease and modality areas: breast, gastrointestinal (GI), genitourinary (GU), leukemia, lymphoma, myeloma, neuro-oncology, respiratory, experimental therapeutics (rare cancers), cancer control and transplant.
The Alliance was formed by the merger of three legacy clinical trials groups: the American College of Surgeons Oncology Group (ACOSOG), the Cancer and Leukemia Group B (CALGB), and the North Central Cancer Treatment Group (NCCTG).[3] The merger was completed in 2014.
- ^ Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer
- ^ Suh, Kangho; Veena Shankaran, M. D.; Bansal, Aasthaa (10 May 2022). "Assessing Surveillance Utilization and Value in Commercially Insured Patients With Colorectal Cancer". The American Journal of Managed Care. 28 (5): e163–e169. doi:10.37765/ajmc.2022.89147. PMC 9316744. PMID 35546589.
- ^ Bertagnolli, Monica (February 2012). "New Alliance formed to address clinical trials in oncology". Bulletin of the American College of Surgeons. American College of Surgeons. Retrieved 27 September 2015.